Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...
ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round
China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...
Ascentage Pharma Receives Drug Production License for Suzhou Plant
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...
Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...
Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo
The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...
Huadong Medicine Partners with Dongyang Med for Equity Collaboration
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang...
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...
Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global...
Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...
Anyeep Raises RMB 100 Million in Series A Financing for Mass Spectrometry Development
Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million...
Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine
China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study...
China Resources Double-Crane Gains Approval for Definity in China
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the...
XtalPi Partners with CK Life Sciences to Develop AI Cancer Vaccine Platform
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life...
Bliss Bio’s BB-1709 Accepted for Review by China’s CDE
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...
Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...
AnchorDx’s UriFind Receives Breakthrough Therapy Designation for Urothelial Carcinoma
China-based Guangzhou AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has obtained a...
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...
Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market...